Clinical Trial Update: IL-4(38-37)-PE38KDEL Immunotoxin in Treating Patients With Recurrent Malignant Astrocytoma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluates the IL-4(38-37)-PE38KDEL immunotoxin for recurrent malignant astrocytoma, sponsored by Barrett Cancer Center. Current trial s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Astrocytoma

Drugs mentioned

• IL-4(38-37)-PE38KDEL immunotoxin

Snippet

Sponsor: Barrett Cancer Center | Conditions: Brain and Central Nervous System Tumors | Phase 1 | Status: UNKNOWN